- Home
- ANTX vs COCH Comparison
ANTX vs COCH Comparison
Compare ANTX & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- COCH
- Stock Information
- Founded
- ANTX 2017
- COCH 1995
- Country
- ANTX United States
- COCH United States
- Employees
- ANTX N/A
- COCH N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- COCH Blank Checks
- Sector
- ANTX Health Care
- COCH Finance
- Exchange
- ANTX Nasdaq
- COCH Nasdaq
- Market Cap
- ANTX 33.2M
- COCH 31.6M
- IPO Year
- ANTX 2022
- COCH N/A
- Fundamental
- Price
- ANTX $1.09
- COCH $1.62
- Analyst Decision
- ANTX Buy
- COCH Strong Buy
- Analyst Count
- ANTX 2
- COCH 2
- Target Price
- ANTX $2.00
- COCH $9.25
- AVG Volume (30 Days)
- ANTX 92.7K
- COCH 30.8K
- Earning Date
- ANTX 08-12-2025
- COCH 08-11-2025
- Dividend Yield
- ANTX N/A
- COCH N/A
- EPS Growth
- ANTX N/A
- COCH N/A
- EPS
- ANTX N/A
- COCH N/A
- Revenue
- ANTX N/A
- COCH $212,000.00
- Revenue This Year
- ANTX N/A
- COCH $5.93
- Revenue Next Year
- ANTX N/A
- COCH $17.69
- P/E Ratio
- ANTX N/A
- COCH N/A
- Revenue Growth
- ANTX N/A
- COCH N/A
- 52 Week Low
- ANTX $0.87
- COCH $1.21
- 52 Week High
- ANTX $2.98
- COCH $3.99
- Technical
- Relative Strength Index (RSI)
- ANTX 52.20
- COCH 58.19
- Support Level
- ANTX $1.05
- COCH $1.56
- Resistance Level
- ANTX $1.10
- COCH $1.80
- Average True Range (ATR)
- ANTX 0.03
- COCH 0.12
- MACD
- ANTX 0.01
- COCH 0.02
- Stochastic Oscillator
- ANTX 83.50
- COCH 60.00
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.